{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:43:49Z","timestamp":1773315829137,"version":"3.50.1"},"reference-count":46,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2011,11,28]],"date-time":"2011-11-28T00:00:00Z","timestamp":1322438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sensors"],"abstract":"<jats:p>Serological thymidine kinase 1 (STK1) is a reliable proliferation marker for prognosis, monitoring tumour therapy, and relapse. Here we investigated the use of STK1 in health screening for early detection of pre-malignant and malignant diseases. The investigation was based on 35,365 participants in four independent health screening studies in China between 2005\u20132011. All participants were clinically examined. The concentration of STK1 was determined by a sensitive chemiluminescent dot blot ECL assay. The ROCvalue of the STK1 assay was 0.96. At a cut-off STK1 value of 2.0 pM, the likelihood (+) value was 236.5, and the sensitivity and the specificity were 0.78 and 0.99, respectively. The relative number of city-dwelling people with elevated STK1 values (\u22652.0 pM) was 0.8% (198\/26,484), while the corresponding value for the group of oil-field workers was 5.8% (514\/8,355). The latter group expressed significantly higher frequency of refractory anaemia, fatty liver, and obesity, compared to the city dwellers, but no cases of breast hyperplasia or prostate hyperplasia. Furthermore, people working in oil drilling\/oil transportation showed higher STK1 values and higher frequency of pre-malignancies and benign diseases than people working in the oil-field administration. In the STK1 elevated group of the city-dwelling people, a statistically significantly higher number of people were found to have malignancies, pre-malignancies of all types, moderate\/severe type of hyperplasia of breast or prostate, or refractory anaemia, or to be at high risk for hepatitis B, compared to people with normal STK1 values (&lt; 2.0 pM). No malignancies were found in the normal STK1 group. In the elevated STK1 group 85.4% showed diseases linked to a higher risk for pre-\/early cancerous progression, compared to 52.4% of those with normal STK1 values. Among participants with elevated STK1 values, 8.8% developed new malignancies or progress in their pre-malignancies within 5 to 72 months, compared to 0.2% among people with normal STK1 values. People who showed elevated STK1 values were at about three to five times higher risk to develop malignancies compared to a calculated risk based on a cancer incidence rate of 0.2\u20130.3%. We conclude that serological TK1 protein concentration is a reliable marker for risk assessment of pre\/early cancerous progression.<\/jats:p>","DOI":"10.3390\/s111211064","type":"journal-article","created":{"date-parts":[[2011,11,28]],"date-time":"2011-11-28T11:13:56Z","timestamp":1322478836000},"page":"11064-11080","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Serological Thymidine Kinase 1 is a Biomarker for Early Detection of Tumours\u2014A Health Screening Study on 35,365 People, Using a Sensitive Chemiluminescent Dot Blot Assay"],"prefix":"10.3390","volume":"11","author":[{"given":"Zhi Heng","family":"Chen","sequence":"first","affiliation":[{"name":"Healthy Centre of the Third XiangYa Hospital, ZhongNan University, ChangSha 410013, China"}]},{"given":"Shou Qing","family":"Huang","sequence":"additional","affiliation":[{"name":"Healthy Centre of the Affiliated Second Hospital, Fujian Chinese Tradition Medicine University, Fuzhou 350108, China"}]},{"given":"Yande","family":"Wang","sequence":"additional","affiliation":[{"name":"Jilin Oil Field General Hospital, Jilin 131106, China"}]},{"given":"Ai Zhen","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Clinical and Laboratory Medicine, Nanjing 81 Hospital, Jiangsu 210002, China"}]},{"given":"Jian","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Clinical and Laboratory Medicine, Nanjing Tumor Hospital, Nanjing 210011, China"}]},{"given":"Xiao Hong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical and Laboratory Medicine, Zhejiang Cancer Hospital, Hangzhou 310022, China"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"Laboratory of Biochemistry and Molecular Biology Research, Fujian Cancer Hospital of Fujian Medical University Teaching Hospital, Fuzhou 350014, China"}]},{"given":"Qu Bo","family":"Chen","sequence":"additional","affiliation":[{"name":"Chinese Medicine Hospital, Guangdong 510120, China"}]},{"given":"Ying Hong","family":"Wang","sequence":"additional","affiliation":[{"name":"Central Laboratory, Cancer Institute & Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing 100021, China"}]},{"given":"Ellen","family":"He","sequence":"additional","affiliation":[{"name":"Sino-Swedish Molecular Bio-Medicine Research Institute, Shenzhen 518057, China"}]},{"given":"Ji","family":"Zhou","sequence":"additional","affiliation":[{"name":"Sino-Swedish Molecular Bio-Medicine Research Institute, Shenzhen 518057, China"}]},{"given":"Sven","family":"Skog","sequence":"additional","affiliation":[{"name":"Sino-Swedish Molecular Bio-Medicine Research Institute, Shenzhen 518057, China"}]}],"member":"1968","published-online":{"date-parts":[[2011,11,28]]},"reference":[{"key":"ref_1","first-page":"3897","article-title":"Serological thymidine kinase 1 (STK1) indicates an elevated risk for the development of malignant tumours","volume":"28","author":"Chen","year":"2008","journal-title":"Anticancer Res"},{"key":"ref_2","first-page":"35","article-title":"The significance of serum thymidine kinase 1 for the risk screening of cancer development in pre-cancerous diseases","volume":"1","author":"Zhang","year":"2010","journal-title":"J. Chin. Health Manag"},{"key":"ref_3","first-page":"497","article-title":"Elevated serum thymidine kinase 1 predicts risk of pre\/early cancerous progression","volume":"12","author":"Huang","year":"2011","journal-title":"Asian-Pac. J. Cancer Prev"},{"key":"ref_4","unstructured":"Tumor Markers for Diagnosis and Management of Cancer, Cigna, Cigna Healthcare Coverage Position. Coverage Position Number 0172;."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.transproceed.2008.12.015","article-title":"Significance of serum tumor markers carcinoembryonic antigen 19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation","volume":"41","author":"Pissaia","year":"2009","journal-title":"Transplant. Proc"},{"key":"ref_6","unstructured":"Berman, J.J., and Moore, G.W. (2010). Precancer: The Beginning and the End, Jones and Bartlett."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1002\/1097-0142(19841201)54:11<2450::AID-CNCR2820541123>3.0.CO;2-R","article-title":"Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia","volume":"54","author":"Kallander","year":"1984","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01715117","article-title":"Thymidine kinase: A tumor marker with prognostic value for non-Hodgkin\u2019s lymphoma and a broad range of potential clinical applications","volume":"65","author":"Hallek","year":"1992","journal-title":"Ann. Hematol"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1586\/14737159.1.4.428","article-title":"Thymidine kinase: Diagnostic and prognostic potential","volume":"1","author":"Buckwalter","year":"2001","journal-title":"Expert Rev. Mol. Diagn"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1517\/17530059.2.2.129","article-title":"The role of thymidine kinase in cancer diseases","volume":"2","author":"Topolcan","year":"2008","journal-title":"Expert Opin. Med. Diagn"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1200\/JCO.2001.19.11.2778","article-title":"Thymidine kinase as a proliferative marker: Clinical relevance in 1,692 primary breast cancer patients","volume":"19","author":"Broet","year":"2001","journal-title":"J. Clin. Oncol"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0022-1759(03)00062-0","article-title":"Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1","volume":"277","author":"Wu","year":"2003","journal-title":"J. Immunol. Method"},{"key":"ref_13","first-page":"923","article-title":"Thymidine kinase 1 expression in atypical ductal hyperplasia significantly differs from usual ductal hyperplasia and ductal carcinoma in situ: A useful tool in tumour therapy management","volume":"2","author":"Guan","year":"2009","journal-title":"Mol. Med. Rep"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/172460080201700210","article-title":"The half-life of cytosolic thymidine kinase in serum by ECL dot bolt potential marker for monitoring the response to surgery of patients with gastric cancer","volume":"17","author":"Zou","year":"2002","journal-title":"Int. J. Biol. Marker"},{"key":"ref_15","first-page":"1013","article-title":"A comparable study between the concentration and the activity of serum thymdine kinase (S-TK) in human solid tumors","volume":"14","author":"He","year":"2005","journal-title":"Oncol. Rep"},{"key":"ref_16","first-page":"145","article-title":"Serum thymidine kinase 1 (STK1) is a prognostic and monitoring factor in patients with non-small-cell lung cancer","volume":"13","author":"Li","year":"2005","journal-title":"Oncol. Rep"},{"key":"ref_17","first-page":"4753","article-title":"Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer","volume":"26","author":"He","year":"2006","journal-title":"Anticancer Res"},{"key":"ref_18","first-page":"455","article-title":"Thymidine kinase 1: A proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients","volume":"15","author":"Zhang","year":"2006","journal-title":"Oncol. Rep"},{"key":"ref_19","first-page":"705","article-title":"Serological thymidine kinase 1 reflects progression of pre-malignant and malignant tumours during therapy","volume":"1","author":"Xu","year":"2008","journal-title":"Mol. Med. Rep"},{"key":"ref_20","first-page":"831","article-title":"Serum thymidine kinase 1: A proliferation marker for neoplasms immunologic monitoring of elderly people","volume":"5","author":"Zhang","year":"2008","journal-title":"Mod. Oncol. Med"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/03009730802688835","article-title":"Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer","volume":"114","author":"Carlsson","year":"2009","journal-title":"Ups. J. Med. Sci"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/CEJ.0b013e328329d817","article-title":"Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker","volume":"18","author":"Luo","year":"2009","journal-title":"Eur. J. Cancer Prev"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12185-009-0380-8","article-title":"Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors","volume":"90","author":"Xu","year":"2009","journal-title":"Int. J. Hematol"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10147-010-0067-4","article-title":"Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings","volume":"15","author":"Chen","year":"2010","journal-title":"Int. J. Clin. Oncol"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/15257771003738535","article-title":"Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin\u2019s lymphoma","volume":"29","author":"He","year":"2010","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/CEJ.0b013e32833ad320","article-title":"Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas","volume":"19","author":"Li","year":"2010","journal-title":"Eur. J. Cancer Prev"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00432-010-0769-z","article-title":"Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients","volume":"136","author":"Pan","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s12253-009-9222-5","article-title":"The proliferation marker thymidine kinase 1 level is high in normal kidney tubule cells compared to other normal and malignant renal cells","volume":"16","author":"Luo","year":"2010","journal-title":"Pathol. Oncol. Res"},{"key":"ref_29","unstructured":"Underwood, J.C.E. (2010). General and Systematic Pathology, Churchill Livingstone."},{"key":"ref_30","first-page":"12","article-title":"Hyperplasia breast disease are suffered in women","volume":"2","author":"Pang","year":"2010","journal-title":"Zhonlaonnian Baolian"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1158\/1055-9965.243.14.1","article-title":"Estimates of cancer incidence in China for 2000 and projections for 2005","volume":"14","author":"Yang","year":"2005","journal-title":"Cancer Epidemiol. Biomark. Prev"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/15257771003729591","article-title":"Enzymatic regulation of cytosolic thymidine kinase 1 and mitochondrial thymidine kinase 2: A mini review","volume":"29","year":"2010","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"ref_33","first-page":"60","article-title":"Hyperplasia breast disease and breast cancer","volume":"1","author":"Hu","year":"2006","journal-title":"Chin. Hydropower Med"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/(SICI)1097-0142(19960901)78:5<1024::AID-CNCR12>3.0.CO;2-4","article-title":"Lobular neoplasia. Long term risk of breast cancer and relation to other factors","volume":"78","author":"Bodian","year":"1996","journal-title":"Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/dc.20004","article-title":"Atypia in the assessment of breast cancer risk: Implications for management","volume":"30","author":"Vogel","year":"2004","journal-title":"Diag. Cytopathol"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.6004\/jnccn.2006.0041","article-title":"Evolving concepts in the management of lobular neoplasia","volume":"4","author":"Anderson","year":"2006","journal-title":"J. Natl. Compr. Cancer Netw"},{"key":"ref_37","first-page":"177","article-title":"Epidemiological trends of prostate cancer: Retrospect and prospect","volume":"17","author":"Dingwei","year":"2007","journal-title":"China Oncol"},{"key":"ref_38","first-page":"476","article-title":"Women\u2019s diseases screening in 18,073 persons","volume":"30","author":"Duan","year":"2010","journal-title":"Chin. Rural Health Serv. Admin"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0002-9440(10)64132-6","article-title":"Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander?","volume":"158","author":"Shah","year":"2001","journal-title":"Am. J. Pathol"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1158\/1078-0432.CCR-08-1982","article-title":"Prostate cancer-associated gene expression alterations determined from needle biopsies","volume":"15","author":"Qian","year":"2009","journal-title":"Clin. Cancer Res"},{"key":"ref_41","first-page":"117","article-title":"Retrospective analysis of incidental prostatic carcinoma after surgery of BPH: Ten years\u2019 results","volume":"26","author":"Wang","year":"2005","journal-title":"Chin. J. Urol"},{"key":"ref_42","first-page":"68","article-title":"The relationship between pathological grade of incidental prostate carcinoma and patient survival","volume":"35","author":"Li","year":"2008","journal-title":"Chin. Clin. Oncol"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11741-008-0205-1","article-title":"Chinese analysis of 51 cases of incidental prostatic carcinoma","volume":"31","author":"Wang","year":"2008","journal-title":"Shanghai Med. J"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1753-4887.2010.00293.x","article-title":"Magnesium, inflammation, and obesity in chronic disease","volume":"68","author":"Nielsen","year":"2010","journal-title":"Nutr. Rev"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1634\/theoncologist.2009-0285","article-title":"Obesity and cancer","volume":"15","author":"Wolin","year":"2010","journal-title":"Oncologist"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1470-2045(10)70141-8","article-title":"Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: Pooled analyses of 424 519 participants","volume":"11","author":"Parr","year":"2010","journal-title":"Lancet Oncol"}],"container-title":["Sensors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8220\/11\/12\/11064\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:58:08Z","timestamp":1760219888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8220\/11\/12\/11064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,28]]},"references-count":46,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2011,12]]}},"alternative-id":["s111211064"],"URL":"https:\/\/doi.org\/10.3390\/s111211064","relation":{},"ISSN":["1424-8220"],"issn-type":[{"value":"1424-8220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,28]]}}}